Development toward a triple-marker biosensor for diagnosing cardiovascular disease

Anna Deng, Daniel Matloff, Chi En Lin, David Probst, Theresa Broniak, Maryam Alsuwailem, Jeffrey LaBelle

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Cardiovascular disease (CVD) is the leading cause of death in the United States and is responsible for 30% of all deaths globally.1 The diagnosis and management of CVD requires monitoring of multiple biomarkers, which comprehensively represents the state of the disease. However, many assays for cardiac biomarkers today are complicated and laborious to perform. Rapid and sensitive biosensors capable of giving accurate measurements of vital cardiac bio-markers without complex procedures are thus in high demand. In the work presented below, rapid, label-free biosensor prototypes for three Food and Drug Administration–approved biomarkers are reported: B-type natriuretic peptide (BNP), cardiac troponin I (cTnI), and C-reactive protein (CRP). The sensors were prepared by immobilizing each biomarker’s antibody onto gold working electrodes with platinum counter and silver/silver chloride reference electrodes. The sensors were tested using electrochemical impedance spectroscopy (EIS), a femto-molar sensitive technique capable of label-free, multi-marker detection if a biomarker’s optimal frequency (OF) can be identified. The OFs of BNP, cTnI, and CRP were found to be 1.74, 37.56, and 253.9 Hz, respectively. The performance of the BNP biosensor was also evaluated in blood and achieved clinically relevant detection limits of 100 pg/mL.

Original languageEnglish (US)
Pages (from-to)169-178
Number of pages10
JournalCritical Reviews in Biomedical Engineering
Volume47
Issue number2
DOIs
StatePublished - Jan 1 2019

Fingerprint

Biomarkers
Biosensors
Labels
Silver
Proteins
Electrodes
Sensors
Electrochemical impedance spectroscopy
Antibodies
Platinum
Assays
Blood
Gold
Monitoring
Natriuretic Peptides

Keywords

  • Biomarkers
  • Cardiovascular disease
  • Electrochemical impedance spectroscopy
  • Imaginary impedance
  • Multi-marker biosensor
  • Optimal frequency

ASJC Scopus subject areas

  • Biomedical Engineering

Cite this

Deng, A., Matloff, D., Lin, C. E., Probst, D., Broniak, T., Alsuwailem, M., & LaBelle, J. (2019). Development toward a triple-marker biosensor for diagnosing cardiovascular disease. Critical Reviews in Biomedical Engineering, 47(2), 169-178. https://doi.org/10.1615/CritRevBiomedEng.2019026532

Development toward a triple-marker biosensor for diagnosing cardiovascular disease. / Deng, Anna; Matloff, Daniel; Lin, Chi En; Probst, David; Broniak, Theresa; Alsuwailem, Maryam; LaBelle, Jeffrey.

In: Critical Reviews in Biomedical Engineering, Vol. 47, No. 2, 01.01.2019, p. 169-178.

Research output: Contribution to journalArticle

Deng, A, Matloff, D, Lin, CE, Probst, D, Broniak, T, Alsuwailem, M & LaBelle, J 2019, 'Development toward a triple-marker biosensor for diagnosing cardiovascular disease', Critical Reviews in Biomedical Engineering, vol. 47, no. 2, pp. 169-178. https://doi.org/10.1615/CritRevBiomedEng.2019026532
Deng, Anna ; Matloff, Daniel ; Lin, Chi En ; Probst, David ; Broniak, Theresa ; Alsuwailem, Maryam ; LaBelle, Jeffrey. / Development toward a triple-marker biosensor for diagnosing cardiovascular disease. In: Critical Reviews in Biomedical Engineering. 2019 ; Vol. 47, No. 2. pp. 169-178.
@article{ac458e78a9584795acefea59014dd6f5,
title = "Development toward a triple-marker biosensor for diagnosing cardiovascular disease",
abstract = "Cardiovascular disease (CVD) is the leading cause of death in the United States and is responsible for 30{\%} of all deaths globally.1 The diagnosis and management of CVD requires monitoring of multiple biomarkers, which comprehensively represents the state of the disease. However, many assays for cardiac biomarkers today are complicated and laborious to perform. Rapid and sensitive biosensors capable of giving accurate measurements of vital cardiac bio-markers without complex procedures are thus in high demand. In the work presented below, rapid, label-free biosensor prototypes for three Food and Drug Administration–approved biomarkers are reported: B-type natriuretic peptide (BNP), cardiac troponin I (cTnI), and C-reactive protein (CRP). The sensors were prepared by immobilizing each biomarker’s antibody onto gold working electrodes with platinum counter and silver/silver chloride reference electrodes. The sensors were tested using electrochemical impedance spectroscopy (EIS), a femto-molar sensitive technique capable of label-free, multi-marker detection if a biomarker’s optimal frequency (OF) can be identified. The OFs of BNP, cTnI, and CRP were found to be 1.74, 37.56, and 253.9 Hz, respectively. The performance of the BNP biosensor was also evaluated in blood and achieved clinically relevant detection limits of 100 pg/mL.",
keywords = "Biomarkers, Cardiovascular disease, Electrochemical impedance spectroscopy, Imaginary impedance, Multi-marker biosensor, Optimal frequency",
author = "Anna Deng and Daniel Matloff and Lin, {Chi En} and David Probst and Theresa Broniak and Maryam Alsuwailem and Jeffrey LaBelle",
year = "2019",
month = "1",
day = "1",
doi = "10.1615/CritRevBiomedEng.2019026532",
language = "English (US)",
volume = "47",
pages = "169--178",
journal = "Critical Reviews in Biomedical Engineering",
issn = "0278-940X",
publisher = "Begell House Inc.",
number = "2",

}

TY - JOUR

T1 - Development toward a triple-marker biosensor for diagnosing cardiovascular disease

AU - Deng, Anna

AU - Matloff, Daniel

AU - Lin, Chi En

AU - Probst, David

AU - Broniak, Theresa

AU - Alsuwailem, Maryam

AU - LaBelle, Jeffrey

PY - 2019/1/1

Y1 - 2019/1/1

N2 - Cardiovascular disease (CVD) is the leading cause of death in the United States and is responsible for 30% of all deaths globally.1 The diagnosis and management of CVD requires monitoring of multiple biomarkers, which comprehensively represents the state of the disease. However, many assays for cardiac biomarkers today are complicated and laborious to perform. Rapid and sensitive biosensors capable of giving accurate measurements of vital cardiac bio-markers without complex procedures are thus in high demand. In the work presented below, rapid, label-free biosensor prototypes for three Food and Drug Administration–approved biomarkers are reported: B-type natriuretic peptide (BNP), cardiac troponin I (cTnI), and C-reactive protein (CRP). The sensors were prepared by immobilizing each biomarker’s antibody onto gold working electrodes with platinum counter and silver/silver chloride reference electrodes. The sensors were tested using electrochemical impedance spectroscopy (EIS), a femto-molar sensitive technique capable of label-free, multi-marker detection if a biomarker’s optimal frequency (OF) can be identified. The OFs of BNP, cTnI, and CRP were found to be 1.74, 37.56, and 253.9 Hz, respectively. The performance of the BNP biosensor was also evaluated in blood and achieved clinically relevant detection limits of 100 pg/mL.

AB - Cardiovascular disease (CVD) is the leading cause of death in the United States and is responsible for 30% of all deaths globally.1 The diagnosis and management of CVD requires monitoring of multiple biomarkers, which comprehensively represents the state of the disease. However, many assays for cardiac biomarkers today are complicated and laborious to perform. Rapid and sensitive biosensors capable of giving accurate measurements of vital cardiac bio-markers without complex procedures are thus in high demand. In the work presented below, rapid, label-free biosensor prototypes for three Food and Drug Administration–approved biomarkers are reported: B-type natriuretic peptide (BNP), cardiac troponin I (cTnI), and C-reactive protein (CRP). The sensors were prepared by immobilizing each biomarker’s antibody onto gold working electrodes with platinum counter and silver/silver chloride reference electrodes. The sensors were tested using electrochemical impedance spectroscopy (EIS), a femto-molar sensitive technique capable of label-free, multi-marker detection if a biomarker’s optimal frequency (OF) can be identified. The OFs of BNP, cTnI, and CRP were found to be 1.74, 37.56, and 253.9 Hz, respectively. The performance of the BNP biosensor was also evaluated in blood and achieved clinically relevant detection limits of 100 pg/mL.

KW - Biomarkers

KW - Cardiovascular disease

KW - Electrochemical impedance spectroscopy

KW - Imaginary impedance

KW - Multi-marker biosensor

KW - Optimal frequency

UR - http://www.scopus.com/inward/record.url?scp=85067943898&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85067943898&partnerID=8YFLogxK

U2 - 10.1615/CritRevBiomedEng.2019026532

DO - 10.1615/CritRevBiomedEng.2019026532

M3 - Article

AN - SCOPUS:85067943898

VL - 47

SP - 169

EP - 178

JO - Critical Reviews in Biomedical Engineering

JF - Critical Reviews in Biomedical Engineering

SN - 0278-940X

IS - 2

ER -